Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
Reference:
Raj Chovatiya, MD, PhD, MSCI, an associate professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and founder and director of the
David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after
Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch
Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment
Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP
Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for
Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:
